NASDAQ:NVET Nexvet Biopharma plc - Ordinary Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nexvet Biopharma plc - Ordinary Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.72 0.00 (0.00 %) (As of 08/10/2017) Add Share Today's Range$6.72Now: $6.72▼$6.7250-Day Range N/A52-Week Range$2.75Now: $6.72▼$6.76VolumeN/AAverage Volume38,104 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company's platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal's immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company's advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Nexvet Biopharma plc - Ordinary. Previous Next 2.5 Community Rank Outperform VotesNexvet Biopharma plc - Ordinary has received 125 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNexvet Biopharma plc - Ordinary has received 130 “underperform” votes. (Add your “underperform” vote.)Community SentimentNexvet Biopharma plc - Ordinary has received 50.98% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Nexvet Biopharma plc - Ordinary and other stocks. Vote “Outperform” if you believe NVET will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVET will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNexvet Biopharma plc - Ordinary does not currently pay a dividend.Dividend GrowthNexvet Biopharma plc - Ordinary does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nexvet Biopharma plc - Ordinary insiders have not sold or bought any company stock.Percentage Held by Insiders37.00% of the stock of Nexvet Biopharma plc - Ordinary is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.38% of the stock of Nexvet Biopharma plc - Ordinary is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.83 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:NVET Previous Symbol CUSIPN/A CIK1618561 Webwww.nexvet.com Phone+353-1-2158100EmployeesN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive NVET News and Ratings via Email Sign-up to receive the latest news and ratings for NVET and its competitors with MarketBeat's FREE daily newsletter. Nexvet Biopharma plc - Ordinary (NASDAQ:NVET) Frequently Asked Questions What stocks does MarketBeat like better than Nexvet Biopharma plc - Ordinary? Wall Street analysts have given Nexvet Biopharma plc - Ordinary a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nexvet Biopharma plc - Ordinary wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. How were Nexvet Biopharma plc - Ordinary's earnings last quarter? Nexvet Biopharma plc - Ordinary (NASDAQ:NVET) announced its earnings results on Thursday, May, 11th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02. View Nexvet Biopharma plc - Ordinary's earnings history. What other stocks do shareholders of Nexvet Biopharma plc - Ordinary own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nexvet Biopharma plc - Ordinary investors own include Frontline (FRO), Achillion Pharmaceuticals (ACHN), Anthera Pharmaceuticals (ANTH), Sphere 3D (ANY), Arena Pharmaceuticals (ARNA), Yamana Gold (AUY), BioLineRx (BLRX), Caladrius Biosciences (CLBS), Genetic Technologies (GENE) and Keryx Biopharmaceuticals (KERX). When did Nexvet Biopharma plc - Ordinary IPO? (NVET) raised $58 million in an IPO on Thursday, February 5th 2015. The company issued 4,000,000 shares at $13.00-$16.00 per share. BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Piper Jaffray and JMP Securities were co-managers. What is Nexvet Biopharma plc - Ordinary's stock symbol? Nexvet Biopharma plc - Ordinary trades on the NASDAQ under the ticker symbol "NVET." What is Nexvet Biopharma plc - Ordinary's stock price today? One share of NVET stock can currently be purchased for approximately $6.72. What is Nexvet Biopharma plc - Ordinary's official website? The official website for Nexvet Biopharma plc - Ordinary is www.nexvet.com. How can I contact Nexvet Biopharma plc - Ordinary? Nexvet Biopharma plc - Ordinary's mailing address is Unit 5 Sragh Technology Park, Rahan Road, TULLAMORE, R35 FR98, Ireland. The biopharmaceutical company can be reached via phone at +353-1-2158100. This page was last updated on 11/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
